Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 24;41(27):4369–4380. doi: 10.1200/JCO.23.00062

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — Time to locoregional recurrence per molecular class in PORTEC-1. (A) Time to locoregional recurrence in POLE-mutated endometrial cancer. (B) Time to locoregional recurrence in mismatch-repair deficient endometrial cancer. (C) Time to locoregional recurrence in p53 abnormal endometrial cancer. (D) Time to locoregional recurrence in no specific molecular profile endometrial cancer. EBRT, external beam radiotherapy; EC, endometrial cancer; MMRd EC, EC with mismatch repair deficiency (POLE wild-type); NAT, no adjuvant therapy; NSMP EC, EC with no specific molecular profile (POLE wild-type, MMR-proficient, and p53 wild-type); POLEmut EC, EC with a pathogenic mutation of DNA polymerase-ε; p53abn EC, EC with a p53 abnormality (POLE wild-type and MMR-proficient).